A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/03/2013	CA2516660C Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament
12/03/2013	CA2489590C Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
12/03/2013	CA2472678C Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss
12/03/2013	CA2397207C Novel stra6 polypeptides
12/03/2013	CA2240834C Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
12/03/2013	CA2213610C Ingap protein involved in pancreatic islet neogenesis
11/2013
11/30/2013	CA2795550A1 Solid dosage formulations of an orexin receptor antagonist
11/30/2013	CA2790763A1 Aptamer bioconjugate drug delivery device
11/30/2013	CA2779052A1 Pharmaceutical composition of entecavir and process of manufacturing
11/30/2013	CA2778735A1 Induction of arteriogenesis
11/30/2013	CA2778679A1 Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
11/30/2013	CA2778559A1 Induction of arteriogenesis
11/28/2013	WO2013177596A2 Methods for treating gi syndrome and graft versus host disease
11/28/2013	WO2013177594A2 Xylitol-based anti-mucosal compositions and related methods and compositions
11/28/2013	WO2013177559A2 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
11/28/2013	WO2013177536A2 Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)
11/28/2013	WO2013177534A2 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
11/28/2013	WO2013177510A1 Neuronal nicotinic receptor agonists for treating schizophrenia in patients with variants of comt gene
11/28/2013	WO2013177501A2 Aprepitant injectable formulations
11/28/2013	WO2013177498A1 Agonists of neuronal nicotinic acetylcholine receptor a7 subtype for use in the treatment of cognitive symptoms of schizophrenia
11/28/2013	WO2013177494A1 Agonists of neuronal nicotinic acetylcholine receptor a7 subtype for use in the treatment of cognitive symptoms of schizophrenia
11/28/2013	WO2013177492A2 Novel lipase inhibitors, reporter substrates and uses thereof
11/28/2013	WO2013177484A1 Methods of treating depression and pain
11/28/2013	WO2013177478A2 Treatment method
11/28/2013	WO2013177458A1 Compositions for increasing strength, muscle mass, and lean body mass
11/28/2013	WO2013177421A2 Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
11/28/2013	WO2013177420A2 Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
11/28/2013	WO2013177419A2 Lipid nanoparticle compositions and methods of making and methods of using the same
11/28/2013	WO2013177418A1 Methods of regulating cannabinoid receptor activity-related disorders and diseases
11/28/2013	WO2013177367A2 Compounds and methods of use thereof for treating neurodegenerative disorders
11/28/2013	WO2013177349A2 Quinazolinediones as tankyrase inhibitors
11/28/2013	WO2013177275A1 Cranberry xyloglucan oligosaccharide composition
11/28/2013	WO2013177253A2 Fatty acid synthase inhibitors
11/28/2013	WO2013177241A1 Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
11/28/2013	WO2013177226A1 Systems for treating pulmonary infections
11/28/2013	WO2013177224A1 N-substituted benzamides and their use in the treatment of pain
11/28/2013	WO2013177195A1 3',5'-cyclic phosphate prodrugs for hcv infection
11/28/2013	WO2013177170A2 Methods for drug screen using zebrafish model and the compounds screened thereform
11/28/2013	WO2013177168A1 Pyrimidine compounds for the treatment of cancer
11/28/2013	WO2013177142A1 Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission
11/28/2013	WO2013177092A1 Substituted alkynyl pyridine compounds and methods of use
11/28/2013	WO2013177053A1 Pyrimidino [1, 2 -c] quinazolinone derivatives as tyrosine kinases inhibitors
11/28/2013	WO2013177024A1 QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
11/28/2013	WO2013176970A1 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
11/28/2013	WO2013176955A1 Cardioprotective compounds, their use with chemotherapy, and methods for identifying them
11/28/2013	WO2013176877A2 Treatment of addiction and impulse-control disorders using pde7 inhibitors
11/28/2013	WO2013176622A1 A dry powder formulation
11/28/2013	WO2013176567A1 Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
11/28/2013	WO2013176555A1 Improved complexes and compositions containing curcumin
11/28/2013	WO2013176542A1 Glucan fibre
11/28/2013	WO2013176512A1 Panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5, and rk1 produced by microwave irradiation, a method of preparing the panax spp. plant extract, and a composition including the panax spp. plant extract
11/28/2013	WO2013176503A1 Tau protein mediated neurodegenerative disease therapeutic agent
11/28/2013	WO2013176455A1 Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
11/28/2013	WO2013176435A1 Anti-ageing composition containing dehydrogenated abietic acid as active ingredient
11/28/2013	WO2013176434A1 Anti-ageing composition containing trans-cuminic acid as active ingredient
11/28/2013	WO2013176293A1 Novel bicyclic thiazole compounds
11/28/2013	WO2013176272A1 Agent for the prevention and/or improvement of periodontal disease
11/28/2013	WO2013176223A1 Pharmaceutical composition for treating inflammatory disease
11/28/2013	WO2013176054A1 Agent containing ascorbic acid derivative, and use for said agent
11/28/2013	WO2013175805A1 Ghrelin receptor agonists for the treatment of achlorhydria
11/28/2013	WO2013175781A1 Pharmaceutical composition for inhalation
11/28/2013	WO2013175505A1 Elvitegravir solid dispersion
11/28/2013	WO2013175500A1 Delazed release pharmaceutical compositions of salsalate
11/28/2013	WO2013175493A1 Stable oral pharmaceutical compositions
11/28/2013	WO2013175483A1 Process for preparing crystalline sorafenib tosylate
11/28/2013	WO2013175479A1 Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity
11/28/2013	WO2013175474A2 Selective inhibitors of undifferentiated cells
11/28/2013	WO2013175417A1 Pyrrolopyrrolidinone compounds
11/28/2013	WO2013175415A1 Substituted pyrimidine compounds and uses thereof
11/28/2013	WO2013175386A1 Compositions and methods for increasing strength and muscle mass
11/28/2013	WO2013175385A1 Bisphosphonates vinylic monomers and polymers and uses thereof
11/28/2013	WO2013175315A1 Combination comprising parthenolide for use in the treatment of alzheimer's\|disease and other neurodegenerative disorders
11/28/2013	WO2013175303A1 Acid resistant banding solution for two piece hard capsules
11/28/2013	WO2013175297A1 Salts of saxagliptin with organic acids
11/28/2013	WO2013175285A1 Process for preparing ophthalmic suspension of brinzolamde
11/28/2013	WO2013175281A1 Use of substituted 2-phenyl-3h-quinazolin-4-ones and analogs for inhibiting bromodomain and extra terminal domain (bet) proteins
11/28/2013	WO2013175270A1 Improved process for the preparation of strontium ranelate hydrates and new polymorphic form of monohydrate
11/28/2013	WO2013175231A1 Dinuceloside polyphosphates for the treatment of pain
11/28/2013	WO2013175215A1 Triazoles as kv3 inhibitors
11/28/2013	WO2013175211A1 Hydantoin derivatives as kv3 inhibitors
11/28/2013	WO2013175206A1 Novel compounds
11/28/2013	WO2013175205A1 Novel Compounds
11/28/2013	WO2013175116A1 Use of an h4 agonist molecule for treating cystic fibrosis
11/28/2013	WO2013175053A1 Catechol o-methyltransferase activity inhibiting compounds
11/28/2013	WO2013175047A1 Use of a compound of formula (i) to manufacture a medicament for treating gaucher's disease, pharmaceutical composition, a compound of formula (ib) and method for obtaining said compound
11/28/2013	WO2013175013A1 Novel dosage and formulation
11/28/2013	WO2013175011A1 Treatment of preadolescent moderate acne vulgaris
11/28/2013	WO2013175009A1 Ulipristal acetate for prevention and treatment of breast tumors
11/28/2013	WO2013174997A1 Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
11/28/2013	WO2013174962A1 Uracyl spirooxetane nucleosides
11/28/2013	WO2013174947A1 Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
11/28/2013	WO2013174937A1 Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
11/28/2013	WO2013174931A1 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
11/28/2013	WO2013174930A2 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
11/28/2013	WO2013174917A1 Compounds for use in the treatment of autoimmune inflammatory disease
11/28/2013	WO2013174916A1 Indane dimers for use in the treatment of autoimmune inflammatory disease
11/28/2013	WO2013174895A1 Heterocyclyl pyrimidine analogues as tyk2 inhibitors
11/28/2013	WO2013174883A1 Compositions comprising short-acting benzodiazepines
11/28/2013	WO2013174882A1 Composition for treating a circadian rhythm disorder
11/28/2013	WO2013174876A1 Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

1 ... 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 ... 7860